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Case Report
Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with 
Castration-Resistant Prostate Cancer 
Byung-Dal Min, Ho-Won Kang, Won-Tae Kim, Yong-June Kim, Seok Joong Yun, Sang Cheol Lee, 
Wun-Jae Kim
Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel 
and a corticosteroid. After the third cycle of docetaxel administration, he presented with 
dyspnea, cough, sputum, and fever of 39.2
oC. The chest X-ray and chest computed to-
mography (CT) revealed a diffuse reticulonodular shadow in both lungs, which sug-
gested interstitial pneumonitis. Initially, we used empiric broad-spectrum antibiotics 
and high-dose corticosteroids. However, his condition progressively became worse and 
he was transferred to the intensive care unit, intubated, and placed on mechanical 
ventilation. He died 4 days after hospital admission. Here we report this case of fatal 
interstitial pneumonitis after treatment with docetaxel for CRPC. We briefly consider 
docetaxel-induced pneumonitis to make physicians aware of the possibility of pulmo-
nary toxicity so that appropriate treatment can be begun as soon as possible.
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Recently, the detection of prostate cancer has rapidly in-
creased in Korea owing to prostate-specific antigen (PSA) 
testing. However, in many cases, prostate cancer is already 
of an advanced or metastatic state when diagnosed. In 
about 80 percent of these patients, androgen ablation re-
duces serum levels of PSA and relieves the symptoms. But 
in nearly all patients the disease eventually becomes re-
fractory to hormone treatment, thus necessitating alter-
native treatment options. Recently, several large studies 
have reported that docetaxel is effective in terms of survival 
benefit as well as improving quality of life [1] and is consid-
ered as the first-line chemotherapeutic drug for patients 
with castration-resistant prostate cancer (CRPC). The 
main side effects of docetaxel are neutropenia, hyper-
sensitivity reaction, stomatitis, peripheral neuropathy, 
and fluid retention [2]. Interstitial pneumonitis is a rare ad-
verse effect but the mortality rate is high; thus, awareness 
of this toxicity is important.
　Herein, we report the case of a patient with acute 
life-threatening interstitial pneumonitis after docetaxel 
therapy. We believe that this is the first case report about 
interstitial pneumonitis after docetaxel therapy for CRPC 
in Korea.
CASE REPORT
A 69-year-old man was diagnosed as having advanced pros-
tate cancer with multiple bone metastases, and when diag-
nosed, his PSA was 1,149 ng/ml. He underwent both orchi-
ectomy and maximal androgen blockade, and his PSA de-
creased to 3.3 ng/ml. However, 5 months later despite hor-
mone therapy his PSA began to increase. Although at 4 
weeks after the discontinuation of anti-androgen therapy 
we administered estramustine, his PSA still increased to 
32.6 ng/ml. This treatment failure led him to further re-
ceive second-line chemotherapy with docetaxel 10 months 
later. His performance status was 1, and he was a 
nonsmoker. His pretreatment chest X-ray and lung sound 
were normal. According to the TAX 327 protocol, the treat-
ment schedule consisted of intravenous docetaxel (75 
mg/m
2) every 3 weeks over 1 hour with premedication of 
prednisone 5 mg twice daily. During the first cycle, intra-
venous dexamethasone 20 mg was administrated before 
docetaxel to prevent hypersensitivity. After the second cy-Korean J Urol 2012;53:371-374
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FIG. 1. (A) Chest X-ray before docetaxel 
administration, showing no abnormal 
findings in either lung. (B) Chest X-ray 
at admission showing a reticular sha-
dow in both lungs that suggested inter-
stitial pneumonitis.
FIG. 2. Chest computed tomography of 
transverse (A) and coronal (B) views 
showing diffuse reticulation in both 
lungs.
cle of chemotherapy, the patient’s PSA level decreased 
from 32.6 to 2.7 ng/ml. Owing to leucopenia (1x10
3/ul) after 
the second cycle of docetaxel administration, granulocyte 
colony-stimulating factor (G-CSF) was injected and his 
leucocytes increased to 9.4x10
3/ul. The results of liver func-
tion tests and other laboratory findings were within nor-
mal limits. 
　Ten days after the third cycle of docetaxel administration 
(cumulative dosage 350 mg), he presented to the emer-
gency department with dyspnea, cough, sputum, and fever 
of 39.2
oC. The physical examination revealed a mild diffuse 
fine crackle. The patient’s leukocyte count was elevated to 
13.1x10
3/ul, and a blood gas obtained on 5 l/min of nasal O2 
demonstrated a pH of 7.422, pCO2 of 21.4 mmHg, and pO2 
of 58.3 mmHg. The chest X-ray and chest computed tomog-
raphy revealed diffuse reticulonodular shadow in both 
lungs, which suggested interstitial pneumonitis (Figs. 1, 
2). Sputum and blood cultures were negative for Pneumo-
cystis carinii pneumonia, influenza, respiratory syncytial 
virus (RSV), nocardia, and common bacteria. Although the 
cultures and stains for infectious etiologies were negative, 
empiric broad-spectrum antibiotics and high-dose cortico-
steroids (methylprednisolone 500 mg per day) were used 
initially. Empiric therapy was expanded to include vanco-
mycin, ceftriaxone, and piperacillin/tazobactam. Broncho-
scopy and pulmonary lavage (BAL) were scheduled but his 
condition rapidly worsened and the invasive procedure 
was refused by his son. Septic shock developed after 3 days 
of admission. His O2 saturation decreased to 80%, and he 
was transferred to the intensive care unit, intubated, and 
placed on mechanical ventilation. Dopamine was required 
for hypotension. His situation worsened steadily. We per-
formed cardiopulmonary resuscitation but he died 4 days 
after hospital admission.
DISCUSSION
Docetaxel is a taxane antineoplastic agent and inhibits tu-
mor growth by inducing microtubule stabilization and pro-
moting bcl-2 inactivation, thereby sensitizing malignant 
cells to apoptotic stimuli [3]. According to large randomized 
studies, docetaxel not only provides palliative benefits but Korean J Urol 2012;53:371-374
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also improves survival in CRPC patients [1]. On the basis 
of this evidence, docetaxel has been widely accepted as a 
first-choice chemotherapeutic agent for managing CRPC. 
The main adverse effects of docetaxel are neutropenia, alo-
pecia, asthenia, peripheral neuropathy, and peripheral 
edema [2,4]. Paclitaxel, the same class of taxane, is more 
commonly used than docetaxel to treat lung cancer, and an 
incidence rate of approximately 3 to 12% of interstitial 
pneumonitis has been reported [5]. However, pulmonary 
toxicity induced by docetaxel is extremely rare, and only 
a few cases have been reported [4,6]. Moreover, to the best 
of our knowledge, only two cases have been reported in the 
case of prostate cancer [7,8]. Although we cannot explain 
why the pulmonary complication is rare in prostate cancer 
patients, there are several possibilities. First, paclitaxel, 
which is more commonly used for lung cancer, is mixed with 
cremaphore, and this complex is related to the hyper-
sensitivity reaction. On the other hand, docetaxel is mixed 
in ethanol and water rather than with cremaphor; thus, hy-
persensitivity reactions are uncommon with docetaxel. 
Second, prednisolone is commonly combined with docetax-
el to manage CRPC patients, and the adjuvant steroid may 
prevent the hypersensitivity reaction. Third, because the 
lung statuses of prostate cancer patients are usually better 
than those of lung cancer patients, serious interstitial 
pneumonitis may be more rarely reported than in lung can-
cer patients. 
　The mechanism of taxane-induced interstitial pneumo-
nitis is poorly understood, but the allergic type and the 
cell-mediated cytotoxic type have been suggested [9]. The 
docetaxel-induced lung toxicity in the cases that have been 
reported usually occurred after the second to fourth course 
of chemotherapy and was usually relieved with cortico-
steroid therapy [6]. Therefore, a cytotoxic T-cell-mediated 
immunologic reaction is a more convincing mechanism. 
Interestingly, there is perhaps a positive relationship be-
tween the tumor response and lung injury. Our case also 
showed an excellent response to docetaxel therapy, and the 
PSA level dropped from 32.6 to 2.7 ng/ml. Unfortunately, 
however, the pulmonary deterioration was irreversible de-
spite the immediate high-dose corticosteroid therapy.
　Interstitial lung disease is caused by a misdirected im-
mune or healing reaction to a number of factors, including 
infections of the lungs, toxins in the environment, certain 
medications, radiation therapy, and chronic autoimmune 
diseases. Therefore, numerous diagnostic tests must be 
performed to confirm the disease. Among them, BAL or 
transbronchial lung biopsy (TBLB) is necessary to exclude 
other etiologies. BAL fluid from drug-induced IP reveals 
lymphocytic alveolitis, an increase in the number of total 
cells, an increased proportion of neutrophils and eosino-
phils, and a decreased CD4/CD8 ratio. A TBLB from 
drug-induced IP reveals edema and swelling of the alveolar 
septum and interstitial and alveolar mononuclear cell in-
filtration with intraluminal organization and aggregation 
of alveolar macrophages. In this case, however, we could 
not perform the procedure because of the patient’s unstable 
vital signs and the denial of his son. The patient had no oth-
er underlying disease including chronic autoimmune dis-
ease or connective lung disease and thus did not take other 
kinds of drugs. Also, the sputum and blood culture tests 
were negative for the unusual infections. Given the evi-
dence, docetaxel-induced hypersensitivity pneumonitis 
was diagnosed. 
　Although pneumonitis is a rare side effect, the mortality 
rate is high; thus, oncologists should be aware of it. The pa-
tients usually present with a high fever, cough, dyspnea, 
and diffuse lung infiltration. The symptoms develop acute-
ly over 1 to 2 days and rapidly progress despite empiric anti-
biotic therapies and culminate in respiratory failure re-
quiring mechanical ventilation [10]. The treatment of 
choice is the administration of corticosteroid therapy, usu-
ally 30 to 60 mg of prednisolone per day for 2 to 3 weeks, 
or 60 to 240 mg per day in more severe conditions such as 
acute respiratory failure with a slow and careful taper-
ing-off period [10].
　In conclusion, docetaxel-induced interstitial pneumo-
nitis in patients with CRPC is an extremely rare complica-
tion but could be life-threatening. Therefore, physicians 
should take this serious fatal complication into account.
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